The Sharjah Investment and Development Authority (Shurooq) has marked a significant milestone for Ajwan Khorfakkan residences with the launch of Phase 3 sales, unveiling two new residential towers, Layan and Juman. Positioned on the scenic East Coast, Ajwan is quickly gaining prominence as one
Phase 3
Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Perjeta® (pertuzumab) biosimilar HLX11 met the primary endpoint. In 2022, Henlius entered into a license and supply agreement with Organon for the exclusive commercialization rights to two biosimilar candidates, including HLX11. The











